PharmacogeneticsAntidepressive AgentsAntidepressive Agents, TricyclicIndividualized MedicineCytochrome P-450 CYP2D6Polymorphism, GeneticSerotonin Uptake InhibitorsVitamin K Epoxide ReductasesFluoxetineAntidepressive Agents, Second-GenerationAryl Hydrocarbon HydroxylasesBiomarkers, PharmacologicalImipramineAmitriptylineGenotypeDesipramineDepressive DisorderDrug-Related Side Effects and Adverse ReactionsCitalopramNortriptylinePharmaceutical PreparationsMianserinWarfarinDrug TherapyMetabolic Detoxication, DrugPharmacy ResidenciesPolymorphism, Single NucleotideGenetic VariationParoxetineSertralineClomipramineDepressive Disorder, MajorDepressionGenetic TestingDihydrouracil Dehydrogenase (NADP)Antipsychotic AgentsCytochrome P-450 Enzyme SystemMethyltransferasesCyclohexanolsCytochrome P-450 CYP3ADrug DesignDrug InteractionsMixed Function OxygenasesPharmacokineticsSwimmingAdrenergic Uptake InhibitorsAnticoagulantsDrug Dosage CalculationsTreatment Outcome6-MercaptopurineDose-Response Relationship, DrugDothiepinSleep Arousal DisordersAzathioprineClinical Trials as TopicOrganic Anion TransportersCodeineStevens-Johnson SyndromePhenotypeGlucuronosyltransferaseMaprotilinePhenelzineBiotransformationFluvoxamineMonoamine Oxidase InhibitorsGene FrequencyDrug HypersensitivityDepressive Disorder, Treatment-ResistantArylamine N-AcetyltransferaseAllelesDideoxynucleosidesTrazodoneReceptors, Adrenergic, beta-1AcenocoumarolOxidoreductases, N-DemethylatingAnti-Anxiety AgentsGenome, HumanP-GlycoproteinCatechol O-MethyltransferaseForecastingSuicidePsychotropic DrugsAmoxapine